Moonwalk banks $70m to progress siRNA therapy for obesity - Pharmaceutical Technology

Moonwalk says MW101 could spare lean muscle at an infrequent dosing schedule, potentially differentiating it from current obesity options. The company says its siRNA-based approach could spare lean muscle at an infrequent dosing schedule as obesity outcomes are defined by more than just weight loss. Moonwalk says its siRNA-based obesity therapy could preserve lean muscle mass while operating on an infrequent dosing schedule. Credit: Studio Romantic / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you…

Source: Pharmaceutical Technology